Saturday, May 10, 2008 9:19:35 AM
9-May-2008
Change in Directors or Principal Officers
Item 5.02. Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Director Option/SAR Grants
On May 5, 2008, the board of directors of Assisted Living Concepts, Inc. (the "Company") granted awards of tandem non-qualified stock options and stock appreciation rights ("Options/SARs") to the Company's non-management directors (Alan Bell, Jesse Brotz, Derek H.L. Buntain, David J. Hennigar, Malen S. Ng, Mel Rhinelander, Charles H. Roadman II, MD, and Michael J. Spector) pursuant to the 2006 Omnibus Incentive Compensation Plan (the "2006 Omnibus Plan"). Each non-management director was granted 20,000 Options/SARs. The aggregate number of Options/SARs granted was 160,000.
The Options/SARs become exercisable in one-third increments on the first, second and third anniversaries of the grant date. Once exercisable, awards may be exercised either by purchasing shares of the Company's Class A common stock at the exercise price or exercising the stock appreciation right. The Committee has sole discretion to determine whether stock appreciation rights are settled in shares of Class A common stock, cash or a combination of shares of Class A common stock and cash. The Options/SARs have an exercise price of $6.42 per share, the closing price of the Company's Class A common stock on the New York Stock Exchange on May 7, 2008, the second business day following the Company's public release of quarterly financial results, and expire five years from the date of grant.
This summary does not purport to be complete and is subject to and qualified in its entirety by reference to the text of the 2006 Omnibus Plan and the form of Tandem Stock Option/Stock Appreciation Rights Award Agreement, which are filed as Exhibit 10.1 and Exhibit 10.2, respectively, to this Current Report on Form 8-K and incorporated herein by reference. Executive Retirement Plan
On May 5, 2008, the board of directors of the Company approved amendments to the Company's Executive Retirement Plan to conform the Executive Retirement Plan to the requirements of Internal Revenue Code Section 409A. Under the Executive Retirement Plan, the Company makes a book entry to an account each month equal to 10% of the participant's base monthly salary. Participants are not allowed to make contributions to the Executive Retirement Plan. A participant's account is credited with deemed earnings as if it were invested in investment funds designated by the participant from a list of funds determined by the plan administrator. Participants' interests in the accounts vest according to the number of years of employment with the Company as follows: 20% after two years; 40% after three years; 70% after four years; and 100% after five years. A participant's interest in an account also vests upon the death or disability of the participant. During employment amounts are payable from an executive's account only in the case of financial hardship due to unforeseen emergency. Following a participant's separation from the Company for any reason, the participant's vested interest in the account is paid to the participant (or the participant's beneficiary in the event of the participant's death) either in a lump sum or in five, ten or twenty annual installments, as elected by the participant. Payments for reasons other than death or disability are not started until at least six months after separation. Each of the Company's executive officers participates in the Executive Retirement Plan. As of May 5, 2008, the executive officers were vested in their accounts as follows: Ms. Bebo, 100%; Mr. Buono, 0%; Mr. Fonstad, 0%; and Mr. Levonowich, 100%.
This summary does not purport to be complete and is subject to and qualified in its entirety by reference to the text of the Executive Retirement Plan, as amended, which is filed as Exhibit 10.3 to this Current Report on Form 8-K and incorporated herein by reference.
-2-
Deferred Compensation Plan
On May 5, 2008, the board of directors of the Company approved amendments to the Company's Deferred Compensation Plan to conform the Deferred Compensation Plan to the requirements of Internal Revenue Code Section 409A. Under the Deferred Compensation Plan, designated key employees, including each of the Company's executive officers, may elect annually to defer up to 10% of their base salaries. Compensation deferred is retained by the Company and credited to participants' deferral accounts. The Company credits certain participants' (including each of the executive officers') accounts with matching contributions equal to 50% of participants' elective deferrals. Participants are fully vested in their deferral accounts as to amounts they elect to defer. Participants' interests in amounts the Company credits to their accounts as matching contributions vest according to the number of years of employment with the Company as follows: 20% after two years; 40% after three years; 70% after four years; and 100% after five years. The deferral and matching accounts are credited with interest at the prime rate. During employment amounts are payable from an executive's account only in the case of financial hardship due to unforeseen emergency. Following a participant's separation from the Company for any reason, the participant's vested interest in the account is paid to the participant (or the participant's beneficiary in the event of the participant's death) either in a lump sum or in five, ten or twenty annual installments, as elected by the participant. Payments for reasons other than death or disability are not started until at least six months after separation.
This summary does not purport to be complete and is subject to and qualified in its entirety by reference to the text of the Deferred Compensation Plan, as amended, which is filed as Exhibit 10.4 to this Current Report on Form 8-K and incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
10.1 2006 Omnibus Incentive Compensation Plan (incorporated by reference to
Exhibit 10.4 to Current Report of Assisted Living Concepts, Inc. on Form
8-K dated November 10, 2006, File No. 001-13498)
10.2 Form of Director Tandem Stock Option/Stock Appreciation Rights Award
Agreement
10.3 Executive Retirement Program, as amended May 5, 2008
10.4 Deferred Compensation Plan, as amended May 5, 2008
Recent ALC News
- Alcon Publishes Agenda for 2024 Annual General Meeting • Business Wire • 04/07/2024 09:59:00 PM
- Alcon Strengthens Leadership in IOL Innovation with the launch of the Clareon Presbyopia Correcting IOLs in India • Business Wire • 03/12/2024 08:30:00 AM
- Vivity, the World’s Leading EDOF IOL, Reaches One Million Milestone • Business Wire • 03/06/2024 02:55:00 PM
- Vivity, la LIO à profondeur focale accrue première au monde, atteint un million d’implants • Business Wire • 03/06/2024 02:55:00 PM
- Vivity, the World’s Leading EDOF IOL, Reaches One Million Milestone • Business Wire • 03/06/2024 01:00:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/01/2024 11:44:06 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/29/2024 10:56:33 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/29/2024 06:12:20 PM
- Alcon's Broad Portfolio Delivers Robust Sales and Earnings Growth in FY 2023 • Business Wire • 02/27/2024 09:30:00 PM
- Algoma Central Corporation Reports Financial Results for Fiscal 2023 • Business Wire • 02/26/2024 12:00:00 PM
- Algoma Central Corporation to Issue Fiscal 2023 Financial Results on February 26, 2024 • Business Wire • 02/12/2024 09:22:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/01/2024 06:04:56 PM
- Alcon Canada lance les lentilles cornéennes TOTAL30 Multifocal pour les patients porteurs de lentilles réutilisables atteints de presbytie • Business Wire • 02/01/2024 02:02:00 PM
- Algoma Central Corporation continues to grow product tanker business with the acquisition of two additional vessels • Business Wire • 01/18/2024 01:54:00 PM
- Alcon Shares Rise After Dry-Eye Care Drug Shows Promising Results • Dow Jones News • 01/10/2024 09:12:00 AM
- Alcon Reports Results for Dry-Eye-Treatment Trials • Dow Jones News • 01/09/2024 10:20:00 PM
- Alcon Announces Positive Topline Results From Phase 3 COMET Trials of AR-15512, a Novel Topical Drug Candidate for Dry Eye • Business Wire • 01/09/2024 09:30:00 PM
- Alcon Announces Positive Topline Results From Phase 3 COMET Trials of AR-15512, a Novel Topical Drug Candidate for Dry Eye • Business Wire • 01/09/2024 09:30:00 PM
- Lifecore Biomedical Expands Relationship with Existing Long-Term Customer Through a Series of Commercial Arrangements • GlobeNewswire Inc. • 01/05/2024 01:00:00 PM
- Alcon to Present at 2024 Annual J.P. Morgan Healthcare Conference • Business Wire • 12/27/2023 02:01:00 PM
- Alcon Down Over 5%, On Track for Largest Percent Decrease Since May 2022 -- Data Talk • Dow Jones News • 11/15/2023 04:08:00 PM
- Alcon's Swiss Shares Drop After Guidance Narrowed to Lower End of Range • Dow Jones News • 11/15/2023 11:11:00 AM
- Alcon Reports Third Quarter 2023 Results • Business Wire • 11/14/2023 09:30:00 PM
- Alcon Canada lance Clareon Vivity, sa plus récente avancée en matière de LIO pour la correction de la presbytie • Business Wire • 11/08/2023 02:03:00 PM
- Algoma Central Corporation Reports Financial Performance for the 2023 Third Quarter • Business Wire • 11/03/2023 07:00:00 PM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM
Avant Technologies Launches Advanced AI Supercomputing Network and Expansive Data Solutions • AVAI • Apr 23, 2024 8:00 AM
BestGrowthStocks.com Issues Comprehensive Analysis of Triller Merger with AGBA Group Holding Limited • AGBA • Apr 22, 2024 1:00 PM
Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California • BLO • Apr 22, 2024 8:49 AM